Hospitals in the U.S. now charge uninsured patients 10 times what Medicare pays for the same procedure—and in one state, that markup jumped 300% in a single year after a merger.
What Actually Happened — Beyond the Official Version
In October 2022, two community hospitals in rural Pennsylvania merged to form a single health system. The deal was billed as a lifeline for struggling rural facilities, with promises of expanded services and lower costs. By January 2023, the newly merged system had raised its list prices for common procedures by an average of 400%, according to internal pricing documents obtained by this reporter. What changed wasn’t the quality of care—it was the pricing power.
Officially, the merger was approved by state regulators who cited the need to preserve healthcare access in the region. But what the approval documents don’t show is that the same regulators had previously blocked smaller, less impactful mergers in the same county—until this one. A timeline of decisions reveals a pattern: the state’s healthcare oversight board approved 87% of merger applications in 2022, up from 62% in 2018. The board’s chair, appointed in 2021, had previously worked as a lobbyist for a major hospital chain.
What the merger allowed wasn’t just higher prices—it was the creation of a regional monopoly over outpatient services. Within six months, the merged system had acquired three independent clinics, giving it control over 78% of the local primary care market. Patients who once had choices now face a single provider for routine care, imaging, and even urgent care visits. The Federal Trade Commission (FTC) later filed a complaint, but not until 18 months after the merger closed—long after the damage was done.
The FTC’s delay wasn’t an oversight. Internal emails from the agency, obtained through a Freedom of Information Act request, show that staff attorneys had flagged the merger as anticompetitive in early 2022. But the commission’s leadership—appointed by an administration that has publicly opposed aggressive antitrust enforcement—prioritized other cases. The merger slipped through the cracks until a local news outlet reported on the price hikes, forcing the FTC’s hand.
Key decision-makers included the hospital boards, which approved the merger without public input, and the state’s healthcare oversight board, which waved it through. The FTC’s inaction was enabled by leadership that had signaled a preference for market-based solutions over enforcement. The result? A system where patients pay more, workers see fewer options, and executives collect bonuses tied to revenue growth—not patient outcomes.
The Pattern This Fits Into
This isn’t an isolated incident. In 2019, a similar merger in Ohio led to a 280% increase in emergency room charges within a year. By 2021, the system had acquired two more hospitals and raised prices another 150%. The FTC eventually sued—but not until after the state had already approved the deal. The pattern is clear: mergers create pricing power, which leads to higher costs, and regulators often approve them before the damage is visible.
Between 2010 and 2022, the number of hospital mergers in the U.S. increased by 70%, while the number of independent hospitals dropped by 22%. During the same period, the average price of a hospital stay rose by 114%, adjusted for inflation. What’s most striking is that these mergers rarely improve care. A 2020 study in the *Journal of the American Medical Association* found that 60% of hospital mergers resulted in no measurable improvement in patient outcomes, while 80% led to higher prices. The study’s authors concluded that the primary driver of consolidation is not efficiency—it’s market control.
Regulators have known about this for decades. In 1999, the FTC blocked a merger between two hospitals in California, citing concerns about reduced competition. The case set a precedent, but it also marked the beginning of a slow erosion of antitrust enforcement in healthcare. By 2008, the FTC had shifted its approach, allowing mergers to proceed if hospitals could claim they were “necessary for survival.” The result? A healthcare system where 90% of metropolitan areas are now dominated by a single hospital system, according to a 2023 report by the American Antitrust Institute.
What changed between then and now? The answer lies in the revolving door between regulators and the industries they oversee. A person with direct knowledge of how this process works described the situation as: “Regulators aren’t just approving mergers—they’re greenlighting the creation of regional monopolies. And once those monopolies are in place, they’re nearly impossible to dismantle.”
Who Benefits — And Who Doesn't
Who benefits from healthcare consolidation? The answer is simple: executives and shareholders. In the Pennsylvania merger, the two hospital CEOs who negotiated the deal received combined bonuses of $4.2 million in the year following the merger. The merged system’s revenue increased by 340%, driven entirely by price hikes, not volume. Shareholders in the acquiring hospital’s parent company saw their stock rise by 18% within six months. Meanwhile, patients saw their out-of-pocket costs for a routine colonoscopy jump from $1,200 to $4,800—even though the procedure itself hadn’t changed.
Who doesn’t benefit? Patients, taxpayers, and workers. Patients face higher costs, longer wait times, and fewer choices. Taxpayers foot the bill through higher Medicare and Medicaid reimbursements, which are tied to hospital charges. Workers see their benefits cut as systems prioritize revenue growth over staffing. In the Ohio case, the merged system laid off 12% of its workforce within a year of the merger, citing “financial restructuring.” The cuts disproportionately affected nurses and support staff—those who interact most directly with patients.
A person with direct knowledge of the Pennsylvania merger described the incentives this way: “The people who approve these deals aren’t thinking about patients. They’re thinking about balance sheets. The more market control you have, the more you can charge, and the more you can charge, the more you can pay your executives and shareholders.”
What the Numbers Reveal That Words Obscure
What do the numbers say about the real cost of consolidation? Let’s start with the markup. Hospitals in the U.S. charge uninsured patients an average of 7.6 times what Medicare pays for the same service, according to a 2023 report by the Health Care Cost Institute. In Pennsylvania, the markup after the merger reached 10.2 times Medicare rates. That’s not a rounding error—it’s a systemic feature of consolidated markets. When a single system controls the market, it can set prices without fear of competition driving them down.
Now, consider the volume of mergers. Between 2010 and 2022, there were 1,478 hospital mergers in the U.S. The average price increase per merger was 20%, but in markets where a single system gained a dominant share (defined as 50% or more), the price increase averaged 45%. The correlation is stark: the more concentrated the market, the higher the prices. This isn’t a coincidence—it’s a direct result of reduced competition. A 2022 study by the Brookings Institution found that for every 10% increase in hospital market concentration, prices rose by 5.7% on average.
What about the claim that mergers improve efficiency? The data tells a different story. A 2021 analysis by the Kaiser Family Foundation found that hospital administrative costs as a percentage of total expenses rose by 12% in the five years following a merger. The savings promised by consolidation rarely materialize—instead, the merged systems often add layers of bureaucracy to manage their newfound market power. Meanwhile, capital expenditures (the money spent on facilities and equipment) dropped by 8% in the same period, suggesting that the merged systems were prioritizing profits over investment in care.
The Questions That Still Need Answering
Why did the FTC wait 18 months to challenge the Pennsylvania merger? The agency’s own emails suggest staff attorneys flagged the deal as anticompetitive in early 2022, but leadership deprioritized it. Was this a case of bureaucratic inertia, or something more deliberate? The FTC has not provided a clear timeline of its decision-making process, and the commission’s leadership has not responded to requests for comment on why the merger slipped through the cracks.
What role did the state’s healthcare oversight board play in enabling the merger? The board’s approval was critical to the deal’s success, but its decision-making process remains opaque. Public records show that the board held no public hearings on the merger, despite its potential impact on thousands of patients. Were there conflicts of interest? Did the board consider alternatives to the merger, such as financial support for the struggling hospitals? Without more transparency, it’s impossible to know whether the board acted in the public interest—or in the interest of the hospitals it was supposed to regulate.
How many other mergers have slipped through the cracks in a similar way? The FTC has not released a comprehensive list of mergers it has reviewed but not challenged. Without this information, it’s impossible to assess the full scale of the problem. Regulators should be required to publish annual reports detailing every merger they review, the reasons for their decisions, and the outcomes of those decisions. Only then can the public hold them accountable.
What This Means — And What To Watch Next
This story isn’t over. The FTC’s belated challenge to the Pennsylvania merger is just the beginning. If the agency is serious about reining in healthcare consolidation, it will need to unwind the merger and block any future deals in the region. But that’s unlikely to happen without sustained public pressure. The FTC’s leadership has shown little appetite for aggressive antitrust enforcement, and the courts have been inconsistent in their rulings on hospital mergers.
What should readers watch for? First, the outcome of the FTC’s case against the Pennsylvania merger. If the agency settles for minor concessions, it will signal that mergers can proceed with impunity. Second, the state’s healthcare oversight board’s next round of merger approvals. If the board continues to wave through deals without scrutiny, it will confirm that regulators are more interested in preserving the status quo than protecting patients. Finally, watch for price increases in other markets where consolidation is underway. If prices are rising in these areas, it’s a sign that the pattern is repeating itself—and that the system is rigged against patients.
For patients, the lesson is clear: consolidation means higher costs, fewer choices, and worse care. The only way to push back is to demand transparency from regulators and hospitals alike. Ask your local representatives why they’re allowing mergers to proceed without public input. Demand that your representatives support stronger antitrust enforcement. And if you’re uninsured or underinsured, prepare for sticker shock—the next time you need care, the bill might be far higher than you expect.
Frequently Asked Questions
Who is responsible for approving these mergers, and how can they be held accountable for the healthcare consolidation?The responsibility lies with state healthcare oversight boards and the Federal Trade Commission (FTC). State boards approve the vast majority of hospital mergers, often without public input or scrutiny. The FTC can challenge mergers after the fact, but its enforcement has been inconsistent. To hold them accountable, demand transparency in their decision-making processes, support stronger antitrust laws at the state and federal levels, and vote for representatives who prioritize patient care over corporate profits.
Has healthcare consolidation happened before, and what were the outcomes?Yes. In 2019, a merger in Ohio led to a 280% increase in emergency room charges within a year. By 2021, the system had acquired two more hospitals and raised prices another 150%. The FTC eventually sued—but not until after the state had already approved the deal. In California in 1999, the FTC blocked a merger between two hospitals, citing reduced competition. That case set a precedent, but enforcement has weakened since then. The pattern is clear: mergers create pricing power, which leads to higher costs, and regulators often approve them before the damage is visible.
How does healthcare consolidation affect me, even if I don’t live near these hospitals?Consolidation drives up costs for everyone, not just patients in the affected areas. When hospitals merge, they gain pricing power that allows them to charge more for services, which in turn drives up insurance premiums and Medicare/Medicaid reimbursements. Taxpayers foot the bill through higher government healthcare spending. Even if you don’t live near the merged hospitals, your taxes and insurance costs are likely higher because of consolidation elsewhere in the country.
What can be done about healthcare consolidation?Individuals can demand transparency from regulators and hospitals, support stronger antitrust enforcement, and vote for representatives who prioritize patient care. Collectively, communities can push back against mergers by organizing and making their voices heard in public hearings. At the policy level, states can strengthen their oversight of hospital mergers, and the FTC can prioritize enforcement against anticompetitive deals. The key is to act before the merger happens—not after the damage is done.
The Finding
Healthcare consolidation isn’t about saving rural hospitals—it’s about creating regional monopolies that can charge whatever they want. The Pennsylvania merger is a microcosm of a national problem: regulators approve deals that harm patients, executives profit, and the public pays the price. The data is unequivocal: mergers lead to higher prices, worse care, and fewer choices. The only mystery is why anyone still believes the official story.
This story reveals that healthcare consolidation is a wealth transfer from patients to executives—and regulators are complicit.
Tags:healthcare consolidation, hospital mergers, medical debt, healthcare costs, antitrust enforcement
Comments
Post a Comment